[Side Effect Management in the Early Stages of Cabozantinib Administration].
Gan To Kagaku Ryoho
; 48(10): 1269-1271, 2021 Oct.
Article
in Ja
| MEDLINE
| ID: mdl-34657061
ABSTRACT
In 2 patients with postoperative lung metastases from renal cell carcinoma, we administered cabozantinib at a starting dose of 40 mg. The side effects were proteinuria(Grade 2), hand-foot syndrome(Grade 2), and hypertension(Grade 3), which subsided following dose reduction and drug suspension. We believe that a low starting dose of cabozantinib might be a suitable regimen for advanced renal cell carcinoma.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
/
Antineoplastic Agents
Limits:
Humans
Language:
Ja
Journal:
Gan To Kagaku Ryoho
Year:
2021
Document type:
Article